FibroBiologics, Inc. (FBLG) presents a deeply negative liquidation posture as of March 31, 2026. Total assets of $5.9 million are dominated by non-cash, low-recovery items: the operating lease ROU asset ($2.2 million, zero liquidation value), PP&E net ($776K, ~50-70% recovery yielding ~$390-540K), prepaid expenses ($1.0 million, partial recovery at best), and other current assets ($403K, uncertain recovery). Cash and cash equivalents of $1.5 million represent the only high-confidence recovery asset at face value. Under the liquidation lens, total recoverable asset value is approximately $1.5-2.0 million before winding-up costs. Against this, total liabilities of $3.3 million must be settled at face value: current liabilities of $1.8 million (including $246K D&O insurance loan, $723K operating lease current, $850K AP and accrued liabilities), plus $1.5 million non-current operating lease liability. The lease obligation is the critical asymmetry: $2.2 million aggregate operating lease liability (ASC 842) stays at face on liquidation, representing committed future cash outflows of $2.5 million undiscounted through a lease term extending to at least 2030. Net equity at book is $2.6 million, but applying liquidation haircuts to assets and holding liabilities at face produces a material negative recovery to equity. The MFFAIS-reported liquidation values of negative $1.9 million across all three metrics are consistent with this assessment. The company carries an accumulated deficit of $59.2 million and burned $4.4 million in operating cash in Q1 2026. At the current burn rate, the $1.5 million cash balance covers less than five weeks of operations absent external financing. Management has issued an explicit going concern qualification. Compared to the prior filing (10-K, period ending December 31, 2025), the cash position declined by approximately $3.4 million in a single quarter; the convertible notes that were outstanding in the prior period were fully repaid as of November 2025 and no longer appear on the balance sheet, removing that liability but also eliminating prior Yorkville SEPA put option liability complexity. The SEPA facility remains active, generating $706K in equity proceeds in Q1 2026, but at dilutive per-share prices of $5.00-$7.06. Post-period, the company completed an additional equity offering (April 2, 2026 private placement with warrants at $6.90 exercise price) and regained Nasdaq compliance on April 17, 2026; neither event is reflected in the Q1 balance sheet. Filing discusses CDMO manufacturing yield failures for CYWC628 drug product in MD&A but does not separately tag any contingent liability or impairment charge related to this in XBRL.
▼ Community Notes